Oberland Capital agreed to provide up to $400 million into MeiraGTx to push multiple gene therapy prospects toward commercialization. The funding deal is framed as confidence in MeiraGTx’s late-stage commercial potential and includes a specific reference to a recently reacquired asset. MeiraGTx’s roadmap includes candidates positioned for regulatory advancement, and the financing is intended to support the company through commercialization-readiness steps. The announcement also highlights how investors are underwriting pipeline value even after setbacks. For the market, the structure signals continued capital availability for gene therapy platforms with near-term value inflection points.